• Profile
Close

Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis

European Urology Jun 19, 2019

Burdett S, et al. - Via a prospective framework, the researchers intended to review trials on promising therapies for metastatic hormone-sensitive prostate cancer (mHSPC), by adding prostate radiotherapy to androgen deprivation therapy (ADT) or ADT alone. One ongoing (PEACE-1) and two completed (HORRAD and STAMPEDE) eligible trials were identified. On the basis of randomization sequence generation, allocation concealment, completeness of outcome data, and selective outcome reporting, a low risk of bias was noted for both the trials. However, prostate radiotherapy could not clearly improve survival or progression-free survival in unselected men with mHSPC, a clear difference in the effect by the metastatic burden on survival, with an absolute improvement in 3-yr survival in men who had four or fewer bone metastases were observed. Hence, for men with mHSPC with a low metastatic burden prostate radiotherapy should be considered.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay